Surging Beigene Catches Case of Forex Flu
The drug maker’s net loss grew in the third quarter due to weakness in the Chinese yuan, even as its revenue nearly doubledKey Takeaways:Surging sales for its two self-developed drugs…
Recent Articles
RELATED ARTICLES
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
Heated market for dueling blood cancer drugs lands BeiGene in court
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
FAST NEWS: Beigene stock falls after Novartis terminates partnership
BGNE.US 6160.HK
Discover hidden China stock gems in our weekly newsletter